Both α-synuclein and CoQ10 are being pursued as potential therapeutic targets, and international collaborative study groups are promoting this work with CoQ10 supplementation, the preparation of α-synuclein antisense oligonucleotide, and immunisation trials to be conducted in PD and MSA patients by either intravenous or intrathecal routes. This evidence concerns the gene SNCA and Parkinson disease.